Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chagas Disease | 11 | 2025 | 309 | 3.820 |
Why?
|
| Trypanosoma cruzi | 9 | 2025 | 251 | 2.930 |
Why?
|
| HIV Infections | 9 | 2025 | 1955 | 2.250 |
Why?
|
| Immunocompromised Host | 2 | 2024 | 301 | 1.480 |
Why?
|
| Chagas Cardiomyopathy | 6 | 2026 | 51 | 1.430 |
Why?
|
| Emigrants and Immigrants | 3 | 2025 | 162 | 1.330 |
Why?
|
| Strongyloidiasis | 3 | 2025 | 49 | 1.120 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 386 | 1.020 |
Why?
|
| Strongyloides stercoralis | 2 | 2025 | 24 | 0.910 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 658 | 0.840 |
Why?
|
| Teaching Rounds | 1 | 2023 | 30 | 0.790 |
Why?
|
| Veterans | 3 | 2024 | 1726 | 0.730 |
Why?
|
| Herpesvirus 8, Human | 1 | 2021 | 46 | 0.690 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2021 | 41 | 0.690 |
Why?
|
| Contact Tracing | 1 | 2021 | 54 | 0.670 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 48 | 0.670 |
Why?
|
| Health Communication | 1 | 2020 | 31 | 0.670 |
Why?
|
| Immune Tolerance | 1 | 2021 | 148 | 0.670 |
Why?
|
| Helminthiasis | 1 | 2021 | 82 | 0.650 |
Why?
|
| Betacoronavirus | 2 | 2020 | 282 | 0.650 |
Why?
|
| Herpesviridae Infections | 1 | 2021 | 139 | 0.640 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 130 | 0.590 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 142 | 0.580 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 359 | 0.570 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 372 | 0.570 |
Why?
|
| Organ Transplantation | 1 | 2020 | 174 | 0.570 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 253 | 0.560 |
Why?
|
| Pandemics | 3 | 2023 | 1125 | 0.530 |
Why?
|
| HIV | 3 | 2024 | 169 | 0.530 |
Why?
|
| Merozoite Surface Protein 1 | 3 | 2012 | 11 | 0.530 |
Why?
|
| United States | 11 | 2025 | 11149 | 0.510 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 347 | 0.510 |
Why?
|
| Malaria, Falciparum | 3 | 2012 | 67 | 0.510 |
Why?
|
| Plasmodium falciparum | 3 | 2012 | 92 | 0.500 |
Why?
|
| Vaccination | 1 | 2020 | 1001 | 0.460 |
Why?
|
| Humans | 39 | 2026 | 125883 | 0.430 |
Why?
|
| Immunologic Memory | 2 | 2012 | 194 | 0.410 |
Why?
|
| Internship and Residency | 1 | 2023 | 1164 | 0.400 |
Why?
|
| Pacemaker, Artificial | 1 | 2014 | 183 | 0.360 |
Why?
|
| Antibodies, Protozoan | 4 | 2014 | 96 | 0.340 |
Why?
|
| Papillomaviridae | 2 | 2021 | 179 | 0.320 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 3652 | 0.290 |
Why?
|
| Bolivia | 7 | 2017 | 13 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2025 | 781 | 0.280 |
Why?
|
| Female | 21 | 2025 | 67886 | 0.270 |
Why?
|
| Peru | 6 | 2025 | 56 | 0.270 |
Why?
|
| Biomarkers | 3 | 2015 | 3139 | 0.260 |
Why?
|
| Immunoglobulin G | 4 | 2022 | 763 | 0.260 |
Why?
|
| Neoplasms | 1 | 2021 | 2833 | 0.250 |
Why?
|
| Adult | 18 | 2025 | 30246 | 0.250 |
Why?
|
| Strongyloides | 1 | 2025 | 21 | 0.240 |
Why?
|
| Mobile Health Units | 1 | 2025 | 24 | 0.240 |
Why?
|
| Middle Aged | 15 | 2025 | 27322 | 0.230 |
Why?
|
| Insecticides | 2 | 2017 | 50 | 0.230 |
Why?
|
| Trypanocidal Agents | 1 | 2024 | 33 | 0.210 |
Why?
|
| Penile Neoplasms | 1 | 2024 | 37 | 0.210 |
Why?
|
| Risk Factors | 6 | 2025 | 10351 | 0.200 |
Why?
|
| Quality of Health Care | 1 | 2026 | 386 | 0.190 |
Why?
|
| Young Adult | 9 | 2025 | 9583 | 0.190 |
Why?
|
| Noncommunicable Diseases | 1 | 2022 | 19 | 0.190 |
Why?
|
| Coinfection | 1 | 2024 | 183 | 0.190 |
Why?
|
| Internal Medicine | 1 | 2023 | 127 | 0.190 |
Why?
|
| Helminths | 1 | 2022 | 51 | 0.180 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 195 | 0.180 |
Why?
|
| Male | 16 | 2025 | 62056 | 0.170 |
Why?
|
| Kava | 1 | 2020 | 8 | 0.170 |
Why?
|
| Prevalence | 6 | 2025 | 2566 | 0.170 |
Why?
|
| Unemployment | 1 | 2020 | 23 | 0.170 |
Why?
|
| Adolescent | 11 | 2025 | 19934 | 0.170 |
Why?
|
| Data Accuracy | 1 | 2020 | 29 | 0.170 |
Why?
|
| Early Diagnosis | 1 | 2021 | 178 | 0.170 |
Why?
|
| Antigens, Protozoan | 2 | 2012 | 79 | 0.170 |
Why?
|
| Malaria Vaccines | 2 | 2012 | 24 | 0.160 |
Why?
|
| Housing | 1 | 2020 | 52 | 0.160 |
Why?
|
| Retrospective Studies | 4 | 2024 | 16775 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2020 | 88 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 641 | 0.160 |
Why?
|
| Rituximab | 1 | 2021 | 165 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2024 | 1177 | 0.160 |
Why?
|
| Eosinophils | 1 | 2020 | 122 | 0.160 |
Why?
|
| Doxorubicin | 1 | 2021 | 288 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2021 | 181 | 0.160 |
Why?
|
| Food Supply | 1 | 2020 | 90 | 0.160 |
Why?
|
| Mass Screening | 1 | 2025 | 801 | 0.160 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 71 | 0.160 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 128 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 143 | 0.150 |
Why?
|
| Bone Density | 1 | 2022 | 351 | 0.150 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 189 | 0.150 |
Why?
|
| Developing Countries | 1 | 2021 | 299 | 0.150 |
Why?
|
| Inpatients | 1 | 2023 | 538 | 0.150 |
Why?
|
| Public Health | 1 | 2021 | 269 | 0.150 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 185 | 0.150 |
Why?
|
| Syndrome | 1 | 2021 | 1113 | 0.140 |
Why?
|
| B-Lymphocytes | 2 | 2012 | 514 | 0.140 |
Why?
|
| Health Policy | 1 | 2020 | 220 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1145 | 0.140 |
Why?
|
| Endemic Diseases | 2 | 2015 | 58 | 0.140 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 6571 | 0.130 |
Why?
|
| Pyrethrins | 1 | 2017 | 9 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 866 | 0.130 |
Why?
|
| Poverty | 1 | 2020 | 428 | 0.130 |
Why?
|
| Insecticide Resistance | 1 | 2017 | 37 | 0.130 |
Why?
|
| Triatoma | 1 | 2017 | 27 | 0.130 |
Why?
|
| Incidence | 2 | 2024 | 3192 | 0.130 |
Why?
|
| Insect Proteins | 1 | 2017 | 106 | 0.130 |
Why?
|
| Nitriles | 1 | 2017 | 141 | 0.120 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2015 | 276 | 0.120 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2015 | 10 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1819 | 0.120 |
Why?
|
| Aged | 9 | 2024 | 20022 | 0.120 |
Why?
|
| Ventricular Premature Complexes | 1 | 2015 | 17 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2021 | 777 | 0.120 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2015 | 88 | 0.120 |
Why?
|
| Electrocardiography | 3 | 2015 | 917 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 479 | 0.110 |
Why?
|
| Bundle-Branch Block | 1 | 2015 | 38 | 0.110 |
Why?
|
| Antibodies, Helminth | 2 | 2025 | 128 | 0.110 |
Why?
|
| Atrioventricular Block | 1 | 2015 | 44 | 0.110 |
Why?
|
| Chromatography, Affinity | 1 | 2014 | 56 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2015 | 742 | 0.110 |
Why?
|
| Child, Preschool | 8 | 2025 | 14341 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2020 | 675 | 0.110 |
Why?
|
| Insect Control | 1 | 2013 | 11 | 0.100 |
Why?
|
| Aging | 1 | 2020 | 1193 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1429 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 3 | 2025 | 139 | 0.100 |
Why?
|
| Stroke Volume | 1 | 2015 | 490 | 0.100 |
Why?
|
| Child | 10 | 2025 | 25059 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 748 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 351 | 0.090 |
Why?
|
| Animals | 7 | 2025 | 33175 | 0.090 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2012 | 5 | 0.090 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 17 | 0.090 |
Why?
|
| Antigens, CD19 | 1 | 2012 | 170 | 0.080 |
Why?
|
| Protozoan Proteins | 1 | 2012 | 132 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 490 | 0.080 |
Why?
|
| Global Health | 1 | 2014 | 604 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2014 | 529 | 0.070 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 2 | 2015 | 10 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2025 | 228 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2015 | 38 | 0.060 |
Why?
|
| Infant | 5 | 2025 | 12776 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 126 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1548 | 0.050 |
Why?
|
| Antiparasitic Agents | 1 | 2024 | 28 | 0.050 |
Why?
|
| Obesity | 1 | 2015 | 2326 | 0.050 |
Why?
|
| Rural Population | 2 | 2017 | 244 | 0.050 |
Why?
|
| California | 1 | 2024 | 122 | 0.050 |
Why?
|
| Blood Donors | 1 | 2022 | 55 | 0.050 |
Why?
|
| Feces | 1 | 2025 | 701 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 241 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2022 | 282 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 522 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1236 | 0.030 |
Why?
|
| Esterases | 1 | 2017 | 12 | 0.030 |
Why?
|
| Pregnancy | 2 | 2024 | 7392 | 0.030 |
Why?
|
| Nymph | 1 | 2017 | 12 | 0.030 |
Why?
|
| Voltage-Gated Sodium Channels | 1 | 2017 | 13 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2017 | 113 | 0.030 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 11 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 90 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3531 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3417 | 0.030 |
Why?
|
| Troponin I | 1 | 2015 | 82 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2015 | 131 | 0.030 |
Why?
|
| Serum | 1 | 2014 | 43 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2863 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8368 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 566 | 0.020 |
Why?
|
| Overweight | 1 | 2015 | 369 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 3886 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1343 | 0.020 |
Why?
|
| Mali | 1 | 2011 | 12 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 310 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2011 | 116 | 0.020 |
Why?
|
| Echocardiography | 1 | 2015 | 1095 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2033 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 1640 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2763 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2011 | 415 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 757 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 2917 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1408 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5090 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 4890 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 4691 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 1608 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2599 | 0.010 |
Why?
|